TABLE 1.
Demographic and clinical characteristics of critically ill patients included for the development and validation of amikacin population pharmacokinetic model
| Characteristica | Value(s)b
for: |
|
|---|---|---|
| Population group (n = 50) | Validation group (n = 13) | |
| Sex (male/female) (n) | 45/5 | 11/2 |
| Amikacin plasma concn (n) | 80 | 21 |
| Age (yr) | 33.5 (18.0–64.0) | 33.0 (18.0–67.0) |
| Wt (kg) | 70.0 (44.0–138.0) | 70.0 (45.0–127.0) |
| Height (cm) | 170.1 ± 7.9 | 168.0 ± 5.8 |
| BMI (kg/m2) | 24.0 (16.0–38.2) | 23.7 (18.5–41.5) |
| Adjusted wt (kg) | 68.6 (46.0–107.3) | 70.2 (48.6–94.6) |
| Ideal wt (kg) | 68.1 ± 8.1 | 65.9 ± 6.7 |
| Serum creatinine (mg/dl) | 0.8 (0.4–1.8) | 0.8 (0.2–1.4) |
| CLCR (ml/min) | 130.0 ± 40.6 | 140.4 ± 70.3 |
| Urea (mg/dl) | 27.8 (8.5–129.2) | 28.9 (11.9–54.8) |
| Ureic nitrogen (mg/dl) | 13.0 (4.0–60.4) | 14.0 (5.6–25.6) |
| Total proteins (g/dl) | 6.5 ± 1.4 | 4.9 ± 0.9 |
| Albumin (g/dl) | 3.7 ± 0.8 | 2.5 ± 0.6 |
| Total bilirubin (mg/dl) | 0.7 ± 0.3 | 0.4 ± 0.3 |
| Sodium (mmol/liter) | 137.4 ± 4.8 | 140.4 ± 2.9 |
| Potassium (mmol/liter) | 3.8 (3.3–5.0) | 3.9 (3.0–4.5) |
| Chloride (mmol/liter) | 106.6 ± 5.8 | 110.0 ± 4.1 |
| Calcium (mg/dl) | 8.5 ± 0.9 | 8.2 ± 1.1 |
| Phosphorus (mg/dl) | 3.1 ± 1.0 | 3.7 ± 0.8 |
| Magnesium (mEq/liter) | 1.7 ± 0.2 | 1.8 ± 0.2 |
| APACHE II score | 7.8 ± 4.1 | 16.5 ± 2.1 |
| Amikacin dose (mg/day) | 1,000 (500–1,000) | 1,000 (750–1,000) |
| Mechanical ventilation (%) | 14 | 15.4 |
| Pharmacotherapy (%) | ||
| NSAIDs | 88 | 85 |
| Opioid analgesics | 80 | 70 |
| Cephalosporines | 88 | 62 |
| Diuretics | 2 | 15 |
| Antimycotics | 56 | 54 |
| Inotropics | 8 | 8 |
| Glucocorticoids | 20 | 15 |
a
BMI, body mass index; CLCR, creatinine clearance.
b
Data are shown as means ± standard deviations or as medians (ranges).